Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRN-AntimiR-122
- Development stage
- Preclinical
- Lead developer
- Marina Biotech
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CRN-AntimiR-122 is a conformationally restricted nucleotide (CRN)-substituted antisense oligonucleotide (antagomir) developed by Marina Biotech. It is designed to target and inhibit microRNA-122 (miR-122), a liver-specific microRNA that plays a critical role in liver physiology and is a known host factor for hepatitis C virus (HCV) replication. The CRN modification is a proprietary sugar modification that locks the ribose ring in a specific conformation, which significantly enhances hybridization affinity to the target RNA and increases resistance to nuclease degradation. In preclinical studies, CRN-AntimiR-122 demonstrated a dose-dependent de-repression of liver-specific target genes, including Aldolase A (AldoA), Glycogen Synthase I (GYS1), and Solute Carrier Family 7 member 1 (SLC7A1), while maintaining a favorable safety and tolerability profile.
- Other names
- CRN-modified AntimiR-122CRN-substituted AntimiR-122CRN-substituted AntimiR targeting microRNA-122
Beyond the preview
Go deeper on CRN-AntimiR-122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRN-AntimiR-122.